electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue
17 Octobre 2023 - 2:00PM
electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic
medicine and wellness company, announced today that gammaCore
therapy will continue to be listed in the United Kingdom’s National
Health Service (NHS) Supply Chain catalogue for an additional two
years through March 17, 2026. The listing, which commenced on June
4, 2019, was scheduled to terminate on March 18, 2024.
“We are delighted the NHS Supply Chain intends
to continue to include the gammaCore device within their framework
agreement, commencing March 2024 through March 2026 with an option
to extend for a further 2 years,” stated Mitch DeShon, Vice
President of Global Sales & Business Development at
electroCore. “Inclusion in this catalogue helps ensure gammaCore
therapy is broadly accessible to patients across the UK who may
benefit from non-invasive vagus nerve stimulation and adds
increased validation to the benefits realized by patients in the UK
using gammaCore therapy.”
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine and wellness company
dedicated to improving health through its non-invasive vagus nerve
stimulation (“nVNS”) technology platform. Our focus is the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
About gammaCore™gammaCore™ (nVNS) is the first
non-invasive, hand-held medical therapy applied at the neck to
treat migraine and cluster headache through the utilization of a
mild electrical stimulation to the vagus nerve that passes through
the skin. Designed as a portable, easy-to-use technology, gammaCore
is self-administered by patients, as needed, without the potential
side effects associated with commonly prescribed drugs. When placed
on a patient’s neck over the vagus nerve, gammaCore stimulates the
nerve’s afferent fibers, which may lead to a reduction of pain in
patients.
gammaCore™ is intended to provide non-invasive vagus nerve
stimulation (nVNS) on the side of the neck for preventive treatment
of migraine and the acute treatment of pain associated with
migraine in patients 12 and older. gammaCore is also indicated for
adjunctive use for preventive treatment of cluster headache, acute
treatment of episodic cluster headache, and treatment of hemicrania
continua and paroxysmal hemicrania in adult patients.
gammaCore should not be used by people with an active
implantable medical device. Please refer to gammaCore.com or the
Instructions for Use for complete safety information, including
indications, contraindications, warnings, cautions, and
instructions.
Forward-Looking Statements
This press release and other written and oral
statements made by representatives of electroCore may contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include, but are not limited to, statements about
electroCore's business prospects and clinical and product
development plans; its pipeline or potential markets for its
technologies; the timing, outcome and impact of regulatory,
clinical and commercial developments; the business, operating or
financial impact of such studies; the commercial potential of nVNS
generally and gammaCore in particular in the UK and other
statements that are not historical in nature, particularly those
that utilize terminology such as "anticipates," "will," "expects,"
"believes," "intends," other words of similar meaning, derivations
of such words and the use of future dates. Actual results could
differ from those projected in any forward-looking statements due
to numerous factors. Such factors include, among others, the
ability to raise the additional funding needed to continue to
pursue electroCore’s business and product development plans, the
inherent uncertainties associated with developing new products or
technologies, the ability to commercialize gammaCore™, the
potential impact and effects of COVID-19 on the business of
electroCore, electroCore’s results of operations and financial
performance, and any measures electroCore has and may take in
response to COVID-19 and any expectations electroCore may have with
respect thereto, competition in the industry in which electroCore
operates and overall market conditions. Any forward-looking
statements are made as of the date of this press release, and
electroCore assumes no obligation to update the forward-looking
statements or to update the reasons why actual results could differ
from those projected in the forward-looking statements, except as
required by law. Investors should consult all of the information
set forth herein and should also refer to the risk factor
disclosure set forth in the reports and other documents electroCore
files with the SEC available at www.sec.gov.
Contact:ECOR Investor Relations(973)
302-9253investors@electrocore.com
electroCore (NASDAQ:ECOR)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
electroCore (NASDAQ:ECOR)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024